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Abstract 
Background: Ipilimumab is a cytotoxic T-lymphocyte-associated protein 4 receptor antibody used for immuno-
therapy in cancer. Several immune-related adverse events are known. Steroid responsive encephalopathy associated 
with autoimmune thyroiditis is an autoimmune encephalopathy associated with Hashimoto’s Disease and elevated 
serum levels of the related antibodies (anti-thyroid-peroxidase antibody or anti-thyroglobulin antibody). Our case 
implies that steroid responsive encephalopathy associated with autoimmune thyroiditis may be another previously 
unreported side effect of ipilimumab therapy.
Case presentation: We report the case of a 64 years old caucasian patient with prostatic cancer who received ipili-
mumab therapy in a clinical trial. He presented with aphasia, tremor and ataxia, myocloni, hallucinations, anxiety and 
agitation in turns with somnolence. Cranial nerves, deep tendon reflexes, motor and sensory functions were normal. 
Electroencephalography showed background slowing but no epileptic discharges. Brain magnetic resonance imag-
ing was normal and showed no signs of hypophysitis. Cerebrospinal fluid findings ruled out infection and neoplastic 
meningitis. Anti-thyroid antibodies (anti-thyroid-peroxidase antibody and anti-thyroglobulin antibody) were heavily 
increased. Assuming steroid responsive encephalopathy associated with autoimmune thyroiditis the patient was 
treated with 1,000 mg methylprednisolone i.v. for 3 days and continued with 1 mg/kg orally. On the 3rd day of treat-
ment the patient’s condition started to improve. Within the next few days he gradually returned to his previous state, 
and electroencephalography eventually showed only slight slowing. Seven months later the patient’s condition was 
stable, and anti-thyroid antibodies were no more detectable.
Conclusion: Steroid responsive encephalopathy associated with autoimmune thyroiditis may be a hitherto unrec-
ognized complication of ipililumab treatment and should be taken into consideration in patients developing central 
nervous symptoms undergoing this treatment.
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Background
Steroid responsive encephalopathy associated with auto-
immune thyroiditis (SREAT) was previously referred 
to as Hashimoto’s encephalopathy, and is a rare disease. 
It is defined by the occurrence of anti-thyroid anti-
bodies [anti-thyroid-peroxidase antibody (anti-TPO), 
anti-thyroglobulin antibody (anti-TG), anti-α-enolase 
antibodies], and the response to steroids. Symptoms and 
signs include cognitive and memory dysfunction, confu-
sion, psychiatric disturbances, focal and generalized epi-
leptic seizures, stroke-like episodes, myoclonus, ataxia, 
tremor, and choreatiform movements. SREAT may pre-
sent as an acute, subacute or even chronic illness. The 
most consistent cerebrospinal fluid (CSF) finding is an 
elevated protein level without pleocytosis. The immu-
noglobulin G index is usually normal, oligoclonal bands 
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are found occasionally. Magnetic resonance (MRI) and 
computed tomography (CT) imaging of the brain show 
the whole range of findings from entirely normal to vari-
ous nonspecific abnormalities including cerebral atrophy, 
white matter abnormalities both focal and confluent, cor-
tical irregularities, and vasculitic changes [1, 2].
The association of the disease with anti-thyroid anti-
bodies and the responsiveness of SREAT to steroids or 
other therapies such as plasmapheresis supports the 
hypothesis that this is a disorder that involves immu-
nopathogenic mechanisms. However, it is still debated 
whether anti-thyroid antibodies represent an immu-
nological epiphenomenon in a subset of patients with 
encephalopathic processes or whether they are really 
associated with pathogenic mechanisms of the disorder 
[1, 2].
Ipilimumab (MDX-010, “Yervoy”; Bristol-Myers 
Squibb, Princeton, New Jersey, USA) is licensed by US 
Food and Drug Administration and European Medi-
cines Agency for the treatment of metastatic melanoma. 
It is a fully human IgG1 monoclonal antibody against the 
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) 
receptor. CTLA-4 blockage results in enhanced activa-
tion and expansion of T-lymphocytes. Adverse effects of 
ipilimumab are associated with the enhanced immune 
response. Mainly lymphocyte related inflammations 
arise, e.g. dermatitis, enterocolitis, hepatitis, hypophysi-
tis and others. Adverse effects can be managed with ster-
oid therapy [3, 4]. Our case may present a previously not 
reported side effect of ipilimumab.
Case presentation
Our 64 year old caucasian patient had a history of pros-
tate cancer, diagnosed in 2001 [cT3, cN2, M0, G3, Glea-
son 9; prostate-specific antigen (PSA) 151 µg/l]. He was 
successfully treated with local radiotherapy combined 
with chemical castration for 1 year (complete remis-
sion, PSA nadir 0.01 µg/l). In 2006 a biochemical relapse 
occurred that was treated by androgen ablation. In 2011 
Cholin-Pet CT showed local relapse as well as sus-
pect lymph nodes. PSA was increased to 28.9  µg/l. The 
patient was enrolled into a clinical trial of ipilimumab 
for asymptomatic castration refractory prostate cancer 
(CA184095; NCT01057810) at the National Center for 
Tumor Diseases (NCT), Heidelberg. Starting in August 
2011 he received four infusions of ipilimumab (10  mg/
kg) at 3-week-intervals followed by three infusions at 
3-month-intervals. Ipilimumab treatment was effective 
as PSA dropped and CT showed  tumor regression, but 
the patient also experienced severe adverse effects: he 
had epigastric pain and pruritus, followed by heavy diar-
rhea, one episode leading to exsiccosis and prerenal fail-
ure. In November 2011 hypophysitis was diagnosed by 
decreased thyroid-stimulating hormone (TSH) levels and 
low thyroxine levels, an abnormal thyrotropin-releasing 
hormone test, and low cortisone blood levels. Thyroid 
volume was normal (24  ml) with presence of a small 
nodule (0.5  ml). Anti-thyroid antibodies (anti-TPO and 
anti-TG) were elevated (Table 1). The patient was started 
on l-thyroxine at 50 µg/days and gradually increased to 
100 µg once a day. He also received Prednisolone 50 mg 
once daily, which was gradually reduced and switched 
to hydrocortisone 20  mg/days in January 2012. Follow-
ing a normal Metopirone test in June 2012, hydrocorti-
sone was tapered and stopped in July 2012. Therapy with 
l-thyroxine 100 µg/days was continued. The study medi-
cation was continued within the maintenance phase until 
July 2012.
In August 2012, following surgery of an epigastric her-
nia the patient had severe postoperative intraabdominal 
Table 1 Laboratory findings
Ranges of normal values are given in brackets. Abnormal values are printed in italics.
fT3 free triiodothyronine, fT4 free thyroxine, TRAbs TSH receptor antibodies.
–: not determined.
Serum parameter April 2011 November 2011 June 2012 November 2012 June 2013
TSH (mU/l) 1.31 (0.3–4.2) 0.01 (0.4–4.0) 0.05 (0.47–4.7) 0.23 (0.47–4.7) 0.027 (0.47–4.7)
fT3 (ng/l) 3.08 (2.45–5.93) 2.75 (2.0–4.2) – 2.91 (2.45–5.93) 6.05 (2.45–5.93)
fT4 (ng/l) 11.1 (7.8–24.4) 10.57 (8–18) 15.6 (7.8–24.4) 18.2 (7.8–24.4) 11.57 (7.8–24.4)
Anti-TG (IU/ml) – 285 (<60) – 1,902 (<115) –
Anti-TPO (IU/ml) – 410 (<60) – 138 (<34) 27 (<34)
TRAbs (IU/l) – <0.3 (<1.75) – <0.3 (<1.75) <0.3 (<1.75)
PSA (µg/l) 13.4 (<4) 0.11 (<4) – 0.004 (<4) <0.002 (<4)
Testosteron (ng/ml) – 0.11 (2–7) – <0.1 (3–10.6) –
Prolaktin – 179 (43–375) mU/l – 11.20 (3–25) ng/ml –
Cortisol (ng/ml) – 12.1 (50–250) – – 0.5 (50–250)
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bleeding leading to hypovolemic shock followed by sep-
sis. He physically recovered within 3 weeks, but slight 
personality changes remained. He slowly deteriorated 
suffering from adynamia, memory disturbances, and fluc-
tuating disorientation. When the patient was admitted to 
our hospital in November 2012 he was bedridden, som-
nolent and disoriented. He had episodes of agitation and 
hallucinations, and showed myocloni and intermittent 
focal seizures of his right arm. Deep tendon reflexes were 
normal, but Babinski’s sign was intermittently positive. 
He had no paresis. Cranial CT scan was normal. Electro-
encephalography (EEG) showed generalized slowing with 
prevailing of slow theta and delta waves. CSF cell count, 
glucose, and lactate were normal; protein was 85.2  mg/
dl (normal <50). Serum C-reactive protein was 76  mg/l 
(normal <5), erythrocyte sedimentation rate 86  mm/h. 
Leukocyte count was 10.2/µl, erythrocyte count 4.08/ng, 
haemoglobin 11.4  g/dl. Renal and liver functions were 
normal. Anti-thyroid antibodies (anti-TPO and anti-TG) 
in serum were markedly elevated (Table  1). Antibodies 
associated with vasculitis proved negative. Anti-NMDA-, 
VGKC- or onconeural-antibodies were neither deter-
mined in serum nor in CSF. Cranial MRI scan showed 
mild microangiopathic changes, an old lacunar infarction 
in the right thalamus, and a normal pituitary gland. CT-
Scan of the abdomen and thorax showed stable disease at 
the primary site, and no metastasis. PSA was 0.004 µg/l.
Levetiracetam 1,000 mg bid stopped focal seizures, but 
myoclonus and all other symptoms and signs remained. 
The clinical and laboratory settings lead us to assume 
SREAT. On the 3rd day after admission we started treat-
ment with 1,000  mg methylprednisolone intravenously 
for 3  days. On the 6th day we continued with Predni-
solon 100  mg orally and tapered to 60  mg once a day 
within a week. Episodes of hallucinations and anxious 
agitation were treated with haloperidol 2 mg and loraz-
epam 0.5 mg tid. On the 3rd day of steroid treatment the 
patient began to improve. On the 5th day he was able 
to communicate coherently. The psychiatric symptoms 
disappeared, and the respective medication was discon-
tinued. The patient was still temporally disorientated 
and had slowed psychomotor functions, but gradually 
improved. The EEG improved. Fifteen days after the start 
of steroids the patient was discharged. Prednisolone was 
tapered by 10 mg every 4 weeks.
The patient’s condition further improved. At follow-up 
in June 2013 he only had subtle memory deficits and was 
slightly temporally disoriented but was fully aware of this 
and capable of coping in his daily living. The anti-TPO 
concentration was back to normal (Table 1). Ipilimumab 
therapy was not resumed and the patient received no 
other treatment for his prostate cancer after these com-
plications. He remained in complete remission with 
normal PSA values until the last follow-up so far in July 
2014.
Conclusions
Clinical symptoms and signs, typically elevated anti-thy-
roid antibodies and the exclusion of infectious encepha-
litis, meningeal carcinomatosis and ischemia lead us to 
diagnose SREAT in our patient. The prompt and continu-
ous improvement of symptoms and signs with steroid 
treatment, also favored the diagnosis of SREAT. As we 
did not test for onconeural antibodies we cannot rule out 
paraneoplastic encephalitis which has also been reported 
in patients with prostate cancer [5]. However, para-
neoplastic syndromes are rare in this cancer. Classical 
syndromes include cerebellar degeneration, brainstem 
syndromes and peripheral neuropathy, in descending 
order of frequency. In addition, steroid therapy alone is 
usually not effective and prognosis is poor in classical 
paraneoplastic encephalitis [5, 6].
Prior to ipilimumab therapy our patient had normal 
thyroid hormone levels (Table 1). Anti-TPO and anti-TG 
antibodies were not determined at this point. On diag-
nosis of hypophysitis and later on SREAT both TSH and 
thyroid hormone levels were expectably low, and anti-TPO 
and anti-TG antibodies were elevated (Table 1). Though up 
to 7% of the normal population [7] carry these antibodies 
without having autoimmune thyroiditis ipilimumab ther-
apy in our patient could have boosted these antibodies and 
triggered both hypophysitis and thyroiditis [3, 4].
Ipilimumab therapy has been associated with two cases 
of Hashimoto’s thyroiditis and several cases of Graves’ 
disease caused by anti-TSH receptor antibodies [8, 9].
Encephalitis has been seen in a patient following two 
doses of ipilimumab [10]. He “developed confusion and 
lethargy without abnormalities on central nervous system 
imaging, or in the cerebrospinal fluid”. Steroid therapy 
resolved symptoms, so it could have well been SREAT. 
The authors did not refer to thyroid hormones and anti-
thyroid antibodies. Recently, immune-related meningi-
tis and Guillian–Barré syndrome have been reported in 
patients treated with ipilimumab [11]. Therefore, neuro-
logical complications of ipilimumab therapy may be more 
frequent than realized so far.
According to its approval report ipilimumab should be 
avoided in patients with active autoimmune disease and 
used with caution in patients with a history of autoim-
mune disease. The manufacturer states that ipilimumab 
was tested in patients with adequately controlled hypo-
thyroidism and “seemed to be unproblematic” [12]. Test-
ing anti-thyroid antibodies before starting treatment and 
on follow-up may improve its safety. This would help to 
recognize autoimmune thyroiditis and SREAT as possible 
rare but relevant treatment-related complications.
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Consent
Written informed consent was obtained from the patient 
for publication of this Case Report and any accompany-
ing images. A copy of the written consent is available for 
review by the Editor-in-Chief of this journal.
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